Charcot Neuropathic Osteoarthropathy

Etiology

Charcot neuropathic osteoarthropathy develops as a consequence of peripheral neuropathy, which impairs the normal protective mechanisms that maintain joint integrity. The etiology of this disorder is multifactorial, involving sensory, motor, and autonomic neuropathic components that collectively predispose the foot and ankle to progressive structural failure. Sensory neuropathy eliminates protective pain perception, allowing repetitive microtrauma during daily ambulation to occur unnoticed. Motor neuropathy contributes to muscular imbalance and altered joint loading, while autonomic neuropathy increases regional blood flow through arteriovenous shunting. This hyperemia stimulates osteoclastic activity, accelerating bone resorption and reducing structural strength.

Two primary theories describe the etiopathogenesis of Charcot neuropathic osteoarthropathy. The neurotraumatic theory proposes that unrecognized mechanical trauma in an insensate foot initiates the destructive process, with cumulative microinjuries leading to joint instability and collapse. However, the neurovascular theory emphasizes autonomic dysregulation, in which increased local blood flow and osteoclastic activation lead to rapid bone turnover, weakening the osseous framework and predisposing it to fragmentation even under normal physiological loads. In practice, both mechanisms likely interact, with neuropathy initiating susceptibility and continued weight-bearing amplifying the cycle of damage.

Diabetes mellitus is the most common underlying condition of Charcot neuropathic osteoarthropathy, particularly in patients with long-standing disease, poor glycemic control, or established peripheral neuropathy. Additional etiologies include alcoholism, peripheral nerve injury, spinal cord lesions, congenital insensitivity to pain, and other neuropathic disorders. Trauma—often minor or unrecognized—frequently precipitates the acute onset, acting as a trigger within an already vulnerable biomechanical environment.

Ultimately, the etiology of Charcot neuropathic osteoarthropathy reflects a convergence of neuropathic impairment, altered bone metabolism, and mechanical overload. This interplay creates a self-perpetuating cycle of inflammation, osteolysis, and instability that, without timely intervention, progresses to significant deformity and long-term functional compromise.[3][2][4][5]

Epidemiology

Among individuals with diabetes mellitus, the prevalence of Charcot neuropathic osteoarthropathy is commonly reported in the range of 0.1% to 0.9%. In high-risk patients, eg, people with diabetes with documented peripheral neuropathy, prevalence may increase to up to 29% to 35%.[6] Onset typically occurs in individuals aged 50 to 60 and is more common in those with a longer duration of diabetes.[7] The majority of studies suggest a slightly higher incidence in men.[6][8] Around 20% of those affected will have bilateral foot involvement.[8]

Pathophysiology

The pathophysiology of Charcot neuropathic osteoarthropathy has not yet been fully elucidated, and both neurotraumatic and neurovascular theories have been proposed. However, recent evidence points to a combination of both these theories underlying the pathogenesis of the disease.[9][10] Loss of protective sensation and proprioception leads to unrecognized repetitive microtrauma, triggering a proinflammatory cascade characterized by elevated cytokines, eg, TNF-α, IL-1β, and IL-6.[11][12] 

This inflammatory milieu activates the RANK/RANKL/OPG pathway, promoting osteoclast differentiation and uncontrolled bone resorption.[13][9] Autonomic dysregulation increases blood flow to the foot, stimulating osteoclastic bone resorption, causing osteopenia and further structural weakening.[14] Collectively, these result in osteolysis, joint subluxation, and fragmentation, ultimately destabilizing the foot’s structural integrity.[4][10]

Histopathology

Histopathologic examination reveals features consistent with an active inflammatory and osteolytic process involving both bone and soft tissue. In the acute phase, bone biopsies demonstrate trabecular bone resorption, microfractures, marrow edema, and prominent osteoclastic activity. Woven bone is immature and structurally disorganized with decreased osteocytes and empty lacunae.[15][16]

History and Physical

Collectively, a comprehensive history and detailed examination provide the foundation for early diagnosis, appropriate imaging, and timely offloading—critical steps in preventing irreversible collapse and ensuring optimal long-term outcomes. 

Clinical History

A high index of suspicion is essential for accurate diagnosis of Charcot neuropathic osteoarthropathy, as early clinical findings often mimic those of other inflammatory or infectious conditions. Patients typically present with a warm, erythematous, and edematous foot that is often unilateral and associated with minimal or absent pain due to underlying neuropathy. The onset is usually acute or subacute, frequently following minor trauma such as an ankle sprain or repetitive microtrauma from walking or ill-fitting footwear. The initial incident may not be perceived, leading the patient to continue walking and resulting in a severe inflammatory response.[17][2]

Physical Examination

Physical examination findings associated with Charcot neuropathic osteoarthropathy are characterized by pronounced swelling, erythema, and increased localized temperature, often exceeding that of the contralateral limb by 2 °C or more (as measured with infrared thermography). Importantly, pain is typically minimal or absent despite the apparent severity of findings. The foot may appear clinically unstable, with subtle or overt collapse of the medial or lateral column, depending on the stage at presentation. Palpation often reveals bony prominences, particularly along the midfoot, reflecting early subluxation or fragmentation. Joint effusion may be appreciated at the ankle or subtalar joints in hindfoot involvement.

A key feature distinguishing Charcot from infection is that erythema often decreases with elevation, whereas infectious processes tend to be less positional. Pulses are typically bounding due to autonomic dysregulation, despite the presence of significant edema. Sensory examination reveals loss of protective sensation to monofilament testing, diminished vibration perception, and reduced proprioception. Motor neuropathy may manifest as intrinsic muscle wasting or clawing of the toes. Assessment should include evaluation for deformities, eg, rocker-bottom foot or varus malalignment, as these indicate progression toward chronic stages.[18][19][20][19] Gait evaluation may reveal an antalgic pattern or midfoot instability. In later stages, ulceration may occur at areas of abnormal pressure. Careful inspection of the skin is required to identify preulcerative callus or subtle breakdown, which has significant implications for management.

Radiographic evaluation in early stages may be normal or show subtle subluxations and bone fragmentation. As the disease progresses, collapse of the midfoot with rocker-bottom deformity often becomes apparent. Importantly, osteomyelitis and Charcot arthropathy can coexist, and chronic infection may trigger Charcot activation by amplifying systemic and local inflammatory cytokine production, eg, TNF-α and IL-6. Postsurgical trauma or partial amputations may also precipitate Charcot neuropathic osteoarthropathy by altering biomechanical loading and plantar pressure distribution, resulting in new zones of microtrauma that perpetuate the inflammatory process.[21][17][9]

Evaluation

The evaluation of Charcot neuropathic osteoarthropathy relies on a combination of clinical assessment, laboratory testing, and advanced imaging, with an emphasis on early diagnosis to prevent irreversible deformity. 

Laboratory Evaluation

Routine laboratory markers, eg, white blood cell count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), may or may not be elevated in acute Charcot. They are often significantly elevated in osteomyelitis, which has previously been suggested to aid differentiation. However, current International Working Group on the Diabetic Foot (IWGDF) recommendations do not recommend using these laboratory values to distinguish Charcot neuropathic osteoarthropathy, as strong evidence for their use does not exist.[22][23]

Imaging Evaluation

Plain radiographs

Plain radiographs are the initial imaging modality and are essential for evaluating structural changes. Early radiographs may appear normal or demonstrate only subtle periarticular osteopenia and soft-tissue swelling. As the condition progresses, fragmentation, subluxation, dislocation, and collapse of the medial or lateral column become evident. Weight-bearing radiographs are particularly useful for assessing alignment and structural integrity. Bilateral films should be obtained for comparison, and imaging should be obtained standing if possible.[23]

Magnetic resonance imaging

Magnetic resonance imaging (MRI) is the most sensitive modality for detecting early Charcot changes before radiographic abnormalities appear. MRI demonstrates bone marrow edema, subchondral cysts, joint effusion, and surrounding soft-tissue inflammation. Importantly, MRI helps distinguish Charcot from osteomyelitis: osteomyelitis typically shows diffuse marrow replacement with contiguous soft-tissue ulcers, whereas Charcot demonstrates periarticular edema without a direct ulcer tract. MRI should be performed when a strong clinical suspicion for Charcot neuropathic osteoarthropathy in the setting of normal radiographs exists.[23][24]

Nuclear imaging

Nuclear imaging (eg, labeled leukocyte or technetium scans) may be used when differentiating Charcot from infection remains challenging. Bone scans demonstrate increased uptake in both conditions, whereas labeled leukocyte scans are more specific for infection.[23][25]

Computed tomography

Weight-bearing computed tomography (CT) provides excellent visualization of cortical disruption, fragmentation, and subtle subluxation in advanced disease. CT is particularly helpful for surgical planning when joint reconstruction or arthrodesis is considered.[23]

Additional Diagnostic Studies

Temperature assessment is a valuable clinical adjunct, as acute Charcot typically demonstrates a temperature difference of greater than 2 °C between the affected and contralateral foot. Vascular evaluation, including Doppler studies, may be required when severe edema obscures pulse palpation. Neurological assessment, including monofilament and vibration testing, confirms the presence and extent of peripheral neuropathy, a prerequisite for diagnosis.

Guideline Recommendations

Both the IWGDF and the American Diabetes Association (ADA) recommend the following:

• Maintaining high clinical suspicion for Charcot neuropathic osteoarthropathy in any neuropathic patient presenting with a red, hot, swollen foot.

• Performing bilateral imaging for comparison and using MRI when plain radiographs are inconclusive.

Treatment / Management

Immobilization and Offloading Strategies

Management of acute Charcot neuropathic osteoarthropathy focuses on immobilization and offloading, followed by staged return to protected weight-bearing and, in select cases, reconstructive surgery. The IWGDF 2023 guideline recommends a nonremovable knee-high device (total contact cast) or a removable knee-high device altered to be irremovable. These should be initiated as soon as clinical suspicion arises, even before confirmatory imaging. A removable knee-high device worn at all times may be considered for patients who cannot wear or tolerate a nonremovable device. Immobilization should be continued until clinical remission (resolution of warmth/edema, ≤2 °C temperature difference between the extremities, and radiographic consolidation). Full remission may take months, and immobilization should continue until 4 to 6 weeks past remission.[23][26][27](A1)

Pharmacologic Therapy

Pharmacologic adjuncts have limited and mixed evidence and are not first-line. No strong evidence exists for their use, and so they are not currently recommended. In addition, potential harmful effects on bone healing and iatrogenic fractures exist. Supplementation with calcium and vitamin D is recommended concurrently with immobilization in those with or at risk of deficiency. Doses should follow international guidelines.[23][28][27] When a foot infection or osteomyelitis occurs at the same time as Charcot neuropathic osteoarthropathy, management should occur following IWGDF 2023 infection guideline (bone culture, appropriate targeted antibiotics, and early source control), in parallel with immobilization.(A1)

Surgical Management

Surgical management is reserved for nonbraceable deformity, instability, recurrent/impending ulceration, refractory pain, or failed conservative care. Skin breakdown at the lateral or medial malleolus with ulceration places the patient at a significant risk of osteomyelitis, and these patients should be considered for primary arthrodesis. Numerous reconstruction techniques exist, all associated with high complication rates. 

Procedures range from exostectomy of bony prominences to midfoot beaming or arthrodesis and hindfoot or ankle fusion. No matter the procedure performed, the goal of surgical intervention is to restore plantigrade foot alignment and reduce the likelihood of recurrent ulceration. Ideally, surgical intervention occurs after a period of immobilization to allow inflammation to decrease.[2][23][27][29] Medical optimization, including smoking cessation, HbA1c control under 7% to 8%, and recognizing microvascular or macrovascular disease, can lessen potential complications postoperatively.[30](A1)

Differential Diagnosis

The most important differential diagnosis of Charcot is osteomyelitis as both can appear clinically and radiographically similar. Cellulitis, septic arthritis, gout, pseudogout, foot/ankle sprain or fracture, and deep vein thrombosis are also important differentials. Charcot is misdiagnosed 25% of the time, which can cause significant delay in treatment.[31][32]

Pertinent Studies and Ongoing Trials

Evidence supporting the recommended management of Charcot neuropathic osteoarthropathy emphasizes early offloading and immobilization. Randomized trials demonstrate that nonremovable knee-high devices, eg, total contact casts, significantly improve healing rates and time to remission compared with removable devices. Emerging denosumab trials targeting the RANKL pathway show early promise but remain investigational.[23]

Staging

Stages of Charcot

Common classifications that map the phases of Charcot include the Eichenholtz classification and the Sanders and Frykberg classification.

Eichenholtz classification

The Eichenholtz classification describes the following 3 stages of disease progression based on clinical and radiographic findings:

• Stage 0: pre-Charcot/prodromal
  • Clinically: red, hot, swollen foot. No deformity.
  • Radiographically: no changes are seen yet. Normal radiograph
• Stage I: development/destruction
  • Clinically: Erythema, foot edema, elevated temperature, no pain
  • Radiographically: Bony debris at joints, fragmentation of subchondral bone, joint subluxation, and/or fracture-dislocation
• Stage II: coalescence
  • Clinically: Decreased signs of inflammation
  • Radiographically: Worsening of stage 1 features. Absorption of bony debris with new bone formation. Coalescence of large fragments with sclerosis of bone ends. Some increased stability
• Stage III: consolidation
  • Clinically: Resolution of inflammation. Changes in overall foot architecture due to underlying final bony remodeling that can lead to new pressure points, which are at risk of ulceration
  • Radiographically: Remodeling of affected bones and joints [33]

Sanders and Frykberg 

The Sanders and Frykberg classification is used to type and classify the following 5 common anatomical locations of Charcot in the foot:

1. Metatarsophalangeal to interphalangeal joints: 15%
2. Tarsometatarsal joints: 40%
3. Naviculocuneiform joint, navicular-cuneiform, talonavicular, and calcaneocuboid joints: 30%
4. Ankle and subtalar joints: 10%
5. Calcaneus: 5% [7]

Prognosis

Prognosis depends largely on the timing of diagnosis, adherence to offloading, and metabolic control. When identified in the acute phase and managed with prompt immobilization, most patients achieve remission with preservation of a stable, plantigrade, ulcer-free foot. However, delayed or missed diagnosis can result in irreversible deformity, ulceration, recurrent infection, and a high risk of major amputation.[2][23]

Recurrence or new Charcot events occur in up to 25% to 30% of patients, often involving the contralateral limb within several years. Even with successful limb salvage, patients remain at lifelong risk for ulcer recurrence and reactivation, particularly if neuropathy, peripheral arterial disease, or poor glycemic control persist.[17][23]

Complications

Charcot neuropathic osteoarthropathy carries a high risk of long-term complications when not recognized and treated early. Progressive osseous destruction and joint instability lead to collapse of the foot architecture, resulting in the classic rocker-bottom deformity and altered biomechanics that redistribute plantar pressures to abnormal weight-bearing areas. These structural changes markedly increase the risk of skin breakdown, ulceration, infection, and eventual osteomyelitis.[2][9]

Soft-tissue and infectious complications are common. Chronic ulceration can progress to deep infection or sepsis, often necessitating partial or major amputation if not promptly controlled. Recurrent Charcot activity may occur in the same or contralateral limb, particularly if adherence to offloading is poor or metabolic control remains suboptimal.[10][5]

Offloading and immobilization may result in skin breakdown, pressure ulcers, joint stiffness, muscle atrophy, and deep vein thrombosis due to prolonged immobilization. Regular cast changes, skin inspection, and early therapy following remission are recommended.[23] Postsurgical complications include wound dehiscence, delayed union or nonunion, hardware failure, and recurrent ulceration, especially in patients with neuropathy or vascular compromise. Persistent edema and deformity can also impair balance, contributing to falls and mobility loss.[34][5] Complications may eventually result in limb amputation, which carries a 5-year mortality rate approaching 45% to 50%. Early detection, strict immobilization, glycemic optimization, and coordinated interprofessional management remain essential.[10][35]